NCT03360721View on ClinicalTrials.gov

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 6, 2018

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Castration-Resistant Prostate CarcinomaProstate Adenocarcinoma Without Neuroendocrine DifferentiationStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8
Interventions
DRUG

Abiraterone Acetate

Given PO

DRUG

Apalutamide

Given PO

DRUG

Prednisone

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER